177Lu-based radioligand therapy: A retrospective multicenter analysis to calculate the effective half-life and follow-up dose for the public
Christian Schütze, Markus Borowski, Martin Freesmeyer, Robert Freudenberg, Heribert Hänscheid, Jens Kurth, Marc Rudi Linde, Lara-Christiane Militzer, Bernhard Sattler, Tabea Nikola Schmidt, Paul Soubiran, Mathias Steffner, Lars Stegger, Carsten Wanke, Christi… · Nuklearmedizin - NuclearMedicine · 2026 · Heft 02 · S. 60-68
Bibliografische Angaben
Zusammenfassung
AbstractThe study investigated routinely used radiopharmaceuticals containing lutetium-177 (177Lu), providing reference values for their effective half-life (T1/2,eff). So far, no guidelines regarding discharging this patients exist, are essential to ensure radiation protection of the public. This study contributes to the development of binding discharge criteria regarding 177Lu therapies.This retrospective multicenter study comprised eight nuclear medicine departments. Two commercially available products and two in-house preparations were considered. Radiation measurement methods, in terms of measuring device,…
